Big Pharma wants nano-scavengers in its drugs?

To clean up its drugs that are contaminated with genotoxic ingredients (which
are also carcinogenic), Big Pharma may deploy lab-created, nanosized,
polymer-based scavengers.

But is the cure any safer?

New research explains that:

A variety of chemical compounds, intermediates, and reagents are used during
the process of synthesizing active pharmaceutical ingredients (APIs). Some of
these chemicals, intermediates, and reagents, as well as byproducts of synthetic
processes, can have toxic properties and be present as impurities at low levels
in the API or final drug formulation....

The kinetics of acrolein scavenging in the presence of the API iodixanol and
the scavenging capacity of resins were demonstrated in this
paper.

They found a nanopolymer so efficient it cleans up 97.8% of acrolein without
eating the active pharmaceutical components.

Yum... drugs with nanobots.

"Pharmaceutical genotoxic impurities may induce
genetic mutations, chromosomal breaks, or chromosomal rearrangements, and have
the potential to cause cancer in human," lead researcher Ecevit Yilmaz told In-PharmaTechnologist. "Therefore, exposure to
even low levels of such impurities present in the final API may be of
significant toxicological concern."